ClinicalTrials.gg

Program

ferric maltol

Also written as “Ferric Maltol”, “Ferric maltol suspension” and “Ferric maltol”.

Its studies are mostly in Anemia, Iron-Deficiency · Anemia · Iron Deficiencies · Renal Insufficiency, Chronic, led by 2 companies.

Furthest: phase 3, since Apr 19, 20118 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shield Therapeutics70 open or runningphase 3since Apr 19, 2011Apr 19, 2011none ahead
Beijing Aosaikang Pharmaceutical10 open or runningphase 3since Jul 22, 2026Jul 22, 2026none ahead

Also a collaborator on its studies: medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 19, 2011First study: phase 3 study in Anemia, Iron-DeficiencyNew to Shield TherapeuticsShield Therapeutics · NCT01340872 · 128 enrolled
  2. May 10, 2011Phase 3 study in Anemia, Iron-DeficiencyShield Therapeutics · NCT01352221 · 128 enrolled
  3. Feb 9, 2016Phase 3 study in Anemia, Iron-DeficiencyShield Therapeutics · NCT02680756 · 250 enrolled · United States, Belgium, France and more
  4. Aug 30, 2016Phase 3 study in Renal Insufficiency, ChronicShield Therapeutics · NCT02968368 · 167 enrolled · United States
  5. May 23, 2017Phase 1 study in Iron DeficienciesShield Therapeutics · NCT03181451 · 37 enrolled · United Kingdom
  6. Oct 22, 2020Phase 1 study in Anemia, Iron-DeficiencyShield Therapeutics · NCT04626414 · 32 enrolled · United States
  7. Oct 27, 2021Phase 3 study in AnemiaShield Therapeutics · NCT05126901 · 65 enrolled · United States, Puerto Rico, United Kingdom
  8. Jul 22, 2026Beijing Aosaikang Pharmaceutical's first study: phase 3 study in Anemia, Iron-DeficiencyNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT07739368 · 122 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07739368Anemia, Iron-Deficiency · China3CompletedBeijing Aosaikang PharmaceuticalFeb 20, 2025122
NCT05126901Anemia · United States, Puerto Rico, United Kingdom3CompletedShield TherapeuticsJun 9, 202465
NCT04626414Anemia, Iron-Deficiency · United States1CompletedShield TherapeuticsNov 13, 202032
NCT03181451Iron Deficiencies · United Kingdom1CompletedShield TherapeuticsMar 28, 201837
NCT02968368Renal Insufficiency, Chronic · United States3CompletedShield TherapeuticsJan 18, 2018167
NCT02680756Anemia, Iron-Deficiency · United States, Belgium, France and more3CompletedShield TherapeuticsOct 2018250
NCT01352221Anemia, Iron-Deficiency3CompletedShield TherapeuticsOct 2013128
NCT01340872Anemia, Iron-Deficiency3CompletedShield TherapeuticsOct 2013128

How it is read

Names in the registry

  • “Ferric Maltol”, 4 entries
  • “Ferric maltol suspension”, 1 entry
  • “Ferric maltol”, 1 entry
  • “ST10-021”, 1 entry
  • “ST10”, 1 entry

Codes read as this program: ST10.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.